-
Practice parameters from the aan are strategies for patient management that assist physicians in clinical decision-making. These recommendations are derived from a thorough review that not only summarizes the available evidence-based medicine but, more importantly, assesses the quality of the data being reviewed.
-
Like its cousin selegiline, rasagiline is a selective irreversible inhibitor of monoamine oxidase type B. Rasagiline has been shown to improve the motor and cognitive signs of experimental parkinsonism, and preliminary studies have demonstrated that the compound is more potent than selegiline.
-
According to the pdr,1 16% of patients using sildenafil in clinical trials reported headache compared with only 4% of controls. Kruuse and associates studied the effect of sildenafil use apart from sexual activity in 12 patients with a history of migraine without an aura.
-
Several lines of evidence suggest that ace inhibition and/or angiotensin receptor blockade can be effective for migraine prevention. Lisinopril has already been shown to reduce migraine headache.
-
-
Treatment with natalizumab, an antibody to a4 integrin, led to fewer inflammatory brain lesions and fewer relapses in patients with relapsing multiple sclerosis.
-
Current guidelines for NSAID use in patients at high risk for ulcer disease recommend use of NSAIDs selective for cyclo-oxygenase-2 inhibition or nonselective NSAIDs plus a proton pump inhibitor. This study compared diclofenac plus omeprazole with celecoxib in patients with previous GI hemorrhage. Neither regimen successfully prevented rebleeding, and both exhibited significant toxicities.
-
Screening for lung cancer with helical CT has high costs and uncertain benefits.
-
Ice Cream-Evoked Headaches Study: A Randomized Trial of Accelerated vs Cautious Ice Cream Eating Regimen; Treatment of Antidepressant-Associated Sexual Dysfunction with Sildenafil; Prophylactic Treatment of Migraine with an Angiotensin II Receptor Blocker
-
The FDA has approved cyclosporine ophthalmic emulsion for the treatment of dry eyes due to keratoconjuctivitis sicca (KCS) and associated reduced tear production. Cyclosporine is an immunomodulating agent that increases tear production in patients with KCS.